Amgen Inc. (NASDAQ:AMGN) Stock Has Consensus Price Target of $387.93

Amgen Inc. (NASDAQ:AMGN) has received an average recommendation of “Hold” from the thirty brokerages that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $387.93.

Several brokerages have recently weighed in on AMGN. UBS Group upped their target price on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research report on Friday, October 9th. Guggenheim dropped their target price on Amgen from $388.00 to $378.00 and set a “neutral” rating on the stock in a report on Tuesday, October 13th. Canaccord Genuity Group boosted their price target on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Scotiabank upped their price target on Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. Finally, Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Sunday.

Amgen Stock Performance

NASDAQ:AMGN opened at $438.94 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market capitalization of $237.30 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 3.11 and a beta of 0.41. The firm’s fifty day simple moving average is $416.19 and its 200 day simple moving average is $376.06. Amgen has a twelve month low of $288.00 and a twelve month high of $447.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the firm earned $6.02 EPS. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts expect that Amgen will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Tezspire Phase 3 results: Amgen and AstraZeneca reported that Tezspire produced statistically significant and clinically meaningful improvements in eosinophilic esophagitis, including sustained symptom improvement and histologic remission through 52 weeks. The data could expand Tezspire’s commercial opportunity beyond severe asthma. Tezspire Phase 3 results
• Positive Sentiment: Upcoming oncology presentation: Amgen will host an investor webcast during the European Society for Medical Oncology Congress on October 24. New cancer-drug data could provide additional visibility into the company’s pipeline and growth prospects. Amgen ESMO 2026 presentation
• Positive Sentiment: Higher analyst valuation: Goldman Sachs raised its price target for AMGN to $481, signaling potential upside from recent trading levels and reinforcing improving sentiment toward the company. Goldman Sachs raises Amgen price target
• Positive Sentiment: Strong financial performance: Amgen recently exceeded consensus estimates for quarterly revenue and earnings per share, with revenue up 9.5% year over year. Investors are increasingly viewing the company’s diversified portfolio as capable of delivering renewed growth.
• Neutral Sentiment: Compared with Bristol Myers Squibb, Amgen offers stronger recent top-line growth, while Bristol Myers has a lower valuation and substantial free cash flow. The comparison highlights AMGN’s growth appeal but also its relatively fuller valuation. Amgen versus Bristol Myers Squibb
• Negative Sentiment: At roughly 27 times earnings, AMGN is not a deep-value healthcare stock, and its high debt-to-equity ratio increases sensitivity to execution and pipeline setbacks. Investors still need evidence that newer products can sustain growth as mature medicines face competition.

Insiders Place Their Bets

In other news, SVP Nancy Grygiel sold 2,970 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Amgen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Benchmark Financial Wealth Advisors LLC grew its position in shares of Amgen by 10.5% in the third quarter. Benchmark Financial Wealth Advisors LLC now owns 1,991 shares of the medical research company’s stock valued at $839,000 after purchasing an additional 190 shares during the last quarter. Physician Wealth Advisors Inc. increased its stake in shares of Amgen by 25.5% in the third quarter. Physician Wealth Advisors Inc. now owns 295 shares of the medical research company’s stock worth $124,000 after purchasing an additional 60 shares during the period. Pinnacle Associates Ltd. lifted its position in shares of Amgen by 0.5% during the 3rd quarter. Pinnacle Associates Ltd. now owns 62,390 shares of the medical research company’s stock worth $26,298,000 after purchasing an additional 288 shares during the last quarter. Cohen Investment Advisors LLC lifted its position in shares of Amgen by 0.7% during the 3rd quarter. Cohen Investment Advisors LLC now owns 12,279 shares of the medical research company’s stock worth $5,176,000 after purchasing an additional 84 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Amgen by 5.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 167,256 shares of the medical research company’s stock worth $70,500,000 after purchasing an additional 8,294 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.